Dual antiplatelet therapy in cardiovascular disease: Does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?

Heart

Volumn 96, Issue 21, 2010, Pages 1693-1694

  Warner, Timothy D ^a   Armstrong, Paul C J ^b   Curzen, Nicholas P ^c   Mitchell, Jane A ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG INTERACTION;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12;

EID: 78049275781     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.205724     Document Type: Review

References (18)

1. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83.
2. Bhatt DL. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Am J Cardiol 2009;103:11A-19A.
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;45:494-502. (Pubitemid 32758501)
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
5. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
6. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
7. Hobson AR, Qureshi Z, Banks P, et al. Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition. Platelets 2009;20:386-90.
8. Paul BZS, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A2-induced platelet aggregation. Essential role for P2TAC and alpha 2A receptors. J Biol Chem 1999;274:29108-14.
9. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001;12:443-7.
10. Armstrong PC, Dhanji AR, Tucker AT, et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2010;8:613-5.
11. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8.
12. Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008;118:2139-45.
13. Roy P, Bonello L, Torguson R, et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008;102:1614-7.
14. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev 2006;5:75-86.
15. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
16. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42.
17. AstraZeneca. Ticagrelor NDA 22-433 briefing document for Cardiovascular and Renal Drugs Advisory Committee Meeting, 2010. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM220197pdf. (accessed 30 July 2010).
18. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.